文献速递预防保健、筛查与疫苗妇女保健

尿液HPV检测用于英国一般筛查人群宫颈癌筛查的诊断准确性研究

Urine human papillomavirus testing for cervical screening in a UK general screening population: a diagnostic test accuracy study.
PubMed 文献 · Br J Gen Pract · 2025-11-27

该前瞻性横断面诊断试验在英国西北部纳入1517名提供匹配尿液和宫颈样本的筛查参与者,评估尿液自采样HPV检测的临床性能与可接受性。尿液HPV检测特异性85.19%非劣于宫颈样本的87.80%,检测出24/25(96.0%)的CIN2+病例。尿液自采样可接受,但41.6%参与者仍偏好现行宫颈筛查。

要点

  • 尿液HPV检测特异性85.19%非劣于宫颈样本87.80%(P=0.0004)。
  • 尿液检测检出24/25(96.0%)CIN2+病例。
  • 28.4%参与者偏好尿液自采样,41.6%仍偏好现行筛查。

核心结论

  • 在一般筛查人群中,尿液HPV检测特异性非劣于宫颈样本,且对CIN2+有较高检出率。
  • 尿液自采样对现行筛查参与者可接受,但部分人仍偏好传统筛查,选择权对政策制定重要。

研究设计与样本

  • 前瞻性横断面诊断准确性研究,英国西北部,1517名参与者提供匹配尿液和宫颈样本。
  • 尿液使用首段尿收集装置自采,HPV检测采用Roche Cobas® 8800,阈值同宫颈样本。

主要发现

  • 宫颈样本HPV阳性207/1517(13.6%),尿液HPV阳性245/1517(16.2%)。
  • 阴道镜评估80例后CIN2+发生率为1.6%(25/1517)。
  • 尿液检测检出24/25(96.0%)CIN2+参与者。
  • 尿液特异性85.19%(95%CI 83.28-86.95),宫颈样本87.80%(95%CI 86.03-89.42),相对特异性0.97(95%CI 0.95-0.99)。
  • 41.6%(575/1382)偏好现行宫颈筛查,30.0%(414/1382)无偏好,28.4%(393/1382)偏好尿液自采样。

关键数值与推荐

  • 尿液HPV检测特异性非劣于宫颈样本(P=0.0004)。
  • 尿液检测CIN2+灵敏度为96.0%(24/25)。
  • 特异性:尿液85.19%(95%CI 83.28-86.95) vs 宫颈87.80%(95%CI 86.03-89.42),相对特异性0.97(95%CI 0.95-0.99)。

临床怎么用

  • 尿液自采样HPV检测可作为宫颈筛查的替代选择,尤其适用于拒绝或无法进行窥器检查者。
  • 提供尿液自采样选项可能提高筛查参与率,但需尊重部分人偏好传统筛查。

局限性

  • 研究限于英国西北部一般筛查人群,结果外推需谨慎。
  • 尿液自采样偏好数据仅来自1382名参与者,非全部样本。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Cervical screening uptake is decreasing in the UK, with only 67.5% of those eligible under 50 years old attending in 2022. Barriers include restricted access to screening appointments and poor acceptability of the speculum examination. Urine self-sampling is an alternative cervical screening method that has the potential to improve uptake. AIM: To determine the clinical performance and acceptability of human papillomavirus (HPV)-tested urine for cervical screening in a UK general screening population. DESIGN AND SETTING: Prospective, cross-sectional diagnostic test accuracy study in North-West England. METHOD: Urine was self-collected using a first-void urine (FVU) collection device (DNA Genotek Colli-Pee® 10 ml with urine conservation medium) before obtaining matched routine cervical screening samples. HPV testing used Roche Cobas® 8800 at cervical sample thresholds. A questionnaire evaluated urine self-sampling acceptability. HPV-positive cervical samples underwent reflex cytology, managed under standard NHS protocols, and clinical outcomes were collected. RESULTS: In total, 1517 participants provided matched urine and cervical samples. There were 207 of 1517 (13.6%) cervical and 245 of 1517 (16.2%) urine samples that were HPV positive with a 1.6% (n = 25/1517) incidence of cervical intraepithelial neoplasia (CIN)2+ following colposcopic assessment (n = 80). The specificity of urine was non-inferior (P = 0.0004) to the specificity of cervical samples at 85.19% (95% confidence interval [CI] = 83.28 to 86.95) versus 87.80% (95% CI = 86.03 to 89.42), giving a relative specificity of 0.97 (95% CI = 0.95 to 0.99). Urine detected 24 of 25 (96.0%) participants with CIN2+. In the future, 41.6% (n = 575/1382) of participants would prefer current cervical screening, compared with 30.0% (n = 414/1382) with no preference and 28.4% (n = 393/1382) preferring urine self-sampling. CONCLUSION: HPV-tested urine showed non-inferior specificity to cervical samples in a general screening population. Urine self-sampling was acceptable to current attenders but some prefer traditional screening, making choice an important consideration for policymakers.

来源:Br J Gen Pract,查看原文。版权归原作者所有。

引用

  1. Davies JC, Carter S, Cao J, et al. Urine human papillomavirus testing for cervical screening in a UK general screening population: a diagnostic test accuracy study. Br J Gen Pract. 2025. PMID: 40953936. doi:10.3399/BJGP.2025.0105

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。